Merck & Co Inc MRK Stock Analysis
- NYSE
- Stock
- Market closed · opens Monday 9:30 AM ET
$146.73 down $0.21, 0.14% at close Nov 6
Last close · Previous close $146.94
- Market cap
- At the Nov 6 close
- P/E ratio
- 149.72On last 12 months’ EPS
- Diluted EPS
- $0.98Last 12 months
- Dividend yield
- 2.32%Last 12 months
Price chart
$146.73down $0.21, 0.14%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$146.94Nov 5
- Volume7.63MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume10.55MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $85.80 to $156.92; now $146.73
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
MRK beat the S&P 500 in 5 of 7 periods.
| Period | MRK and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | MRK: up 3.4% S&P 500: down 5.6% | MRK beat the S&P 500 by 9.0 percentage points Beat |
| 3M | MRK: up 15.0% S&P 500: down 4.1% | MRK beat the S&P 500 by 19.1 percentage points Beat |
| YTD | MRK: up 42.3% S&P 500: up 8.7% | MRK beat the S&P 500 by 33.6 percentage points Beat |
| 1Y | MRK: up 76.1% S&P 500: up 10.9% | MRK beat the S&P 500 by 65.2 percentage points Beat |
| Long term | ||
| 3Y | MRK: up 54.1% S&P 500: up 75.0% +15.5% vs +20.5% a year | MRK trailed the S&P 500 by 20.9 percentage points Trailed |
| 5Y | MRK: up 109.4% S&P 500: up 67.8% +15.9% vs +10.9% a year | MRK beat the S&P 500 by 41.6 percentage points Beat |
| 10Y | MRK: up 254.7% S&P 500: up 313.1% +13.5% vs +15.2% a year | MRK trailed the S&P 500 by 58.4 percentage points Trailed |
$10,000 invested in MRK 10 years ago (Nov 4, 2016) would be worth about $35,472 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
MRK beat the S&P 500 in 5 of 7 periods.
| Period | MRK and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | MRK: up 3.4% S&P 500: down 5.6% | MRK beat the S&P 500 by 9.0 percentage points Beat |
| 3M | MRK: up 14.3% S&P 500: down 4.3% | MRK beat the S&P 500 by 18.6 percentage points Beat |
| YTD | MRK: up 39.4% S&P 500: up 7.8% | MRK beat the S&P 500 by 31.6 percentage points Beat |
| 1Y | MRK: up 71.1% S&P 500: up 9.7% | MRK beat the S&P 500 by 61.4 percentage points Beat |
| Long term | ||
| 3Y | MRK: up 40.6% S&P 500: up 68.8% +12.0% vs +19.1% a year | MRK trailed the S&P 500 by 28.2 percentage points Trailed |
| 5Y | MRK: up 79.8% S&P 500: up 56.9% +12.4% vs +9.4% a year | MRK beat the S&P 500 by 22.9 percentage points Beat |
| 10Y | MRK: up 161.4% S&P 500: up 252.6% +10.1% vs +13.4% a year | MRK trailed the S&P 500 by 91.2 percentage points Trailed |
$10,000 invested in MRK 10 years ago (Nov 4, 2016) would be worth about $26,143 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$156.45
Closing high on . Now 6.2% below that record.
Split-adjusted daily closes since Jan 2, 1970.
Stock splits
6
Latest: 1.05-for-1 on . One share bought before the first split is 72 shares today.
All 6 splits
- 1.05-for-1
- 2-for-1
- 3-for-1
- 3-for-1
- 2-for-1
- 2-for-1
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Sep 30, 2026. “Last 12 months” means the four quarters from Oct 1, 2025 to Sep 30, 2026, and balance-sheet figures are as of Sep 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $67.38Bup 4.9%
- Net income
- $2.45Bdown 87.1%
- Diluted EPS
- $0.98down 87.1%
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Dec 31, 2024) | $15.62B | $3.74B | $1.48 |
| Q1 FY25 (Mar 31, 2025) | $15.53B | $5.08B | $2.01 |
| Q2 FY25 (Jun 30, 2025) | $15.81B | $4.43B | $1.76 |
| Q3 FY25 (Sep 30, 2025) | $17.28B | $5.79B | $2.32 |
| Q4 FY25 (Dec 31, 2025) | $16.40B | $2.96B | $1.20 |
| Q1 FY26 (Mar 31, 2026) | $16.29B | −$4.24B | −$1.72 |
| Q2 FY26 (Jun 30, 2026) | $16.61B | −$1.34B | −$0.54 |
| Q3 FY26 (Sep 30, 2026) | $18.09B | $5.07B | $2.04 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $48.70B | $13.05B | $5.14 |
| FY22 (Dec 31, 2022) | $59.28B | $14.52B | $5.71 |
| FY23 (Dec 31, 2023) | $60.12B | $365.00M | $0.14 |
| FY24 (Dec 31, 2024) | $64.17B | $17.12B | $6.74 |
| FY25 (Dec 31, 2025) | $65.01B | $18.25B | $7.28 |
Margins
- Gross 71.8%
- Operating 8.1%
- Net 3.6%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $14.75BLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$18.70BLast 12 months
- Capital spending$3.96BLast 12 months
- 21.9%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $3.04BLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$8.37BLast 12 months
- Total returned$11.41BLast 12 months
77% of free cash flow
Balance sheet
- $11.25BAs of Sep 30, 2026
Cash plus short- and long-term marketable securities on the Sep 30, 2026 balance sheet.
- Total debt$53.78BAs of Sep 30, 2026
- Net debt$42.52BAs of Sep 30, 2026
- 1.35As of Sep 30, 2026
Current assets divided by current liabilities on the Sep 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 1.20As of Sep 30, 2026
Total debt divided by shareholders’ equity on the Sep 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 4 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✗Current ratio improved: not passed
- ✓Share count didn’t rise: passed
- ✗Gross margin improved: not passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- 5.3%Last 12 months
Over the last 12 months, Merck’s net income was 5.3% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 1.9%Last 12 months
Over the last 12 months, Merck’s net income was 1.9% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
Dividends
Cash dividends per share by ex-dividend year, adjusted for splits.
Dividends per share
Data table
| Year | Per share |
|---|---|
| 2016 | $1.77 |
| 2017 | $1.80 |
| 2018 | $1.90 |
| 2019 | $2.16 |
| 2020 | $2.37 |
| 2021 | $2.61 |
| 2022 | $2.80 |
| 2023 | $2.96 |
| 2024 | $3.12 |
| 2025 | $3.28 |
| 2026 (to date) | $2.55 |
Dividend details
- $3.40Per share, last 12 months
Cash dividends per share with ex-dividend dates in the last 12 months.
- Dividend yield2.32%Last 12 months
- $0.85Ex-dividend
The most recent payment per share. Shares bought on or after the ex-dividend date don’t receive it.
- FrequencyQuarterly4 payments in the last 12 months
- up 6.7% a yearFull years 2020–2025
The compound annual growth rate of the full-year dividend per share from 2020 to 2025.
- 15 yearsThrough 2025
How many calendar years in a row the full-year amount has risen, through 2025.
- 346.9%Last 12 months
The share of earnings paid out as dividends over the last 12 months. Lower ratios leave more room to reinvest or raise the dividend.
Payout = Dividends per share ÷ Diluted EPS (both last 12 months)Payout ratio calculator
About Merck & Co Inc
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Headquarters
- New Jersey, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- NYSE
- Asset type
- Common stock
- Price history since
MRK news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
MRK stock FAQ
What is MRK stock’s price today?
Merck (MRK) traded at $146.73 at the close on , down $0.21 (0.14%) from the previous close of $146.94. Over the past 52 weeks it has traded between $85.80 and $156.92.
If you invested $1,000 in MRK 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in MRK on would be worth about $3,547 at the close on , a total return of +254.7%. The same $1,000 would be worth $2,094 if invested five years ago, $1,761 if invested one year ago, $6,715 if invested 20 years ago, and $11,206 if invested 30 years ago. Past performance doesn’t predict future returns.
What is MRK’s P/E ratio?
MRK trades at 149.7 times its diluted earnings over the four quarters to ($0.98 per share), at the close. (How the P/E ratio works.)
How much revenue does Merck make?
Merck reported $67.4 billion of revenue over the four quarters to , up 4.9% from the twelve months before. In its latest quarter (Q3 FY26, ended ) revenue was $18.1 billion, up 4.7% from a year earlier.
Is Merck profitable?
Yes. Merck earned $2.5 billion of net income over the four quarters to , a net margin of 3.6%, and its operating margin was 8.1% (what margins tell you).
What are MRK’s earnings per share?
MRK’s diluted earnings per share were $0.98 over the four quarters to , compared with $7.57 in the twelve months before. The latest quarter (Q3 FY26) brought $2.04 per share, against $2.32 a year earlier (how EPS works).
Does MRK pay a dividend?
Yes. Merck pays a quarterly dividend. The most recent was $0.85 per share, with an ex-dividend date of . Over the last twelve months it paid $3.40 per share, a 2.32% yield at the close, and the full-year dividend has risen 15 years in a row (how dividend yield works).
Based on the last 12 months’ payments ($3.40 per share), and if the next 12 months match the last 12, 100 shares would receive about $340 over 12 months, and $1,000 over 12 months would take about 295 shares, roughly $43,285 at the close. Dividends can change.
What is MRK’s 52-week high and low?
Over the past 52 weeks MRK has traded as low as $85.80 and as high as $156.92. At $146.73 at the close on , it is 6.5% below that high and 71.0% above the low.
What is MRK’s all-time high?
MRK’s highest closing price was $156.45 on , adjusted for stock splits. At $146.73 at the close on , it is 6.2% below that record.
Has MRK stock ever split?
Yes, six times: 2-for-1 on ; 2-for-1 on ; 3-for-1 on ; 3-for-1 on ; 2-for-1 on ; 1.05-for-1 on . One share bought before the first split would be 72 shares today.
How has MRK stock performed?
Including dividends and measured to the close on , MRK has returned +42.3% so far this year and +76.1% over the past year, and +109.4% over five years (+15.9% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Merck in?
Merck is in the Healthcare sector and the Drug Manufacturers - General industry, and is headquartered in New Jersey, USA.
What exchange does MRK trade on?
Merck trades on the NYSE under the ticker symbol MRK. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.